Form 4: Nuvation Bio CMO Sells Shares After Option Exercise

Nuvation Bio's Chief Medical Officer, Liu Dongfang, executed pre-planned option exercises and subsequent sales of Class A Common Stock in November 2025.

Summary

• Chief Medical Officer Liu Dongfang engaged in multiple transactions involving Nuvation Bio Inc. Class A Common Stock.
• On November 17, 2025, 15,000 shares were acquired through option exercise at $1.87 per share and subsequently sold at $4.765 per share.
• On November 19, 2025, another 15,000 shares were acquired through option exercise at $1.87 per share and sold at a weighted-average price of $5.1035 per share.
• The sales prices for the November 19th transaction ranged from $5.00 to $5.21.
• Following these transactions, the reporting person beneficially owns 18,000 shares of Class A Common Stock.
• The transactions were made pursuant to a Rule 10b5-1(c) pre-arranged trading plan.
• The reporting person also acquired 3,000 shares on May 19, 2025, and another 3,000 shares on November 19, 2025, under the Issuer's 2021 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can be perceived negatively, these transactions were pre-planned under a Rule 10b5-1 plan, which mitigates concerns about opportunistic selling. The exercise of options also indicates the insider saw value in the stock.

Positives

• The exercise of stock options indicates that the Chief Medical Officer saw value in exercising options at $1.87, suggesting a belief in the company's value above that price.
• The transactions were executed under a Rule 10b5-1(c) plan, indicating pre-planning and not an immediate reaction to new information.

Negatives

• The Chief Medical Officer sold a significant number of shares (30,000 shares in total) acquired through option exercises, which can be interpreted as a reduction in direct equity exposure.

Future Outlook

Stock options held by the Chief Medical Officer will continue to vest monthly over the 36 months following the one-year anniversary of February 29, 2024, subject to continuous service, with an expiration date of February 27, 2034.

Industry Context

Insider transactions, such as option exercises and subsequent sales, are common in the biotechnology and pharmaceutical industries, often reflecting executives monetizing vested equity or managing personal finances. The use of a Rule 10b5-1 plan suggests these were pre-scheduled and not reactive to immediate company news.

Stakeholder Impact

• Shareholders: May view the insider selling as a slight negative, though the pre-planned nature (10b5-1) reduces the impact. The reduction in direct beneficial ownership by a key executive could be noted.

Next Steps

• Continued monthly vesting of remaining stock options over the next 36 months, subject to continuous service.

Key Dates

Recommendation

While the Chief Medical Officer sold shares, these transactions were executed under a pre-arranged Rule 10b5-1 plan, suggesting they are routine and not indicative of new negative information. The exercise of options at a lower price and subsequent sale at a higher price is a common practice for executives to realize compensation. Without additional context on company performance or strategic shifts, this Form 4 alone does not warrant a change from a 'hold' position, as it's a standard insider compensation event.

Keywords

Nuvation Bio, NUVB, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Chief Medical Officer, Liu Dongfang, Equity Transaction, Rule 10b5-1